Clinical Trial: Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer

U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07166367) titled 'Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer' on Sept. 03.

Brief Summary: This study is designed to study the efficacy of ASLAN 001 plus capecitabine for previously irradiated, progressing CNS metastases for HER2+ breast cancer patients.

Study Start Date: Aug. 11, 2016

Study Type: INTERVENTIONAL

Condition: HER2-positive Breast Cancer

Intervention: DRUG: ASLAN001

400mg of Oral ASLAN001 is administered twice daily, every day of each 21-day cycle

DRUG: Capecitabine

1000mg/m^2 of Oral Capecitabine is administered twice daily, on Days 1-14 of a 21-day cycle

Recru...